News Search Results
Mar 05, 2026, 09:30 ET Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales
worldwide."Snook's appointment comes as Slingshot Biosciences experiences rapid adoption of its synthetic cell mimic platform among pharmaceutical companies, biotechnology firms, clinical diagnostics laboratories, and academic research institutions. His leadership will be critical in capitalizing on the growing demand
More news about: Slingshot Biosciences
Mar 05, 2026, 09:28 ET Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online
DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced that Dr. Charles Stacey, Chief Executive Officer of Cerecin, delivered
More news about: Cerecin Inc.
Mar 05, 2026, 09:01 ET More Than Half of GLP-1 Users Reported Seeking Follow-Up Care for Side Effects, Phenomix Sciences Report Finds
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today released new findings from its "2026 State of Obesity Treatment Report: Progress, Gaps, and the Path to Personalized Care" report.
More news about: Phenomix Sciences
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ: ONCY), Vir Biotechnology (NASDAQ: VIR), Iovance Biotherapeutics (NASDAQ: IOVA), C4 Therapeutics (NASDAQ: CCCC), and Immunocore (NASDAQ: IMCR).
More news about: Equity Insider
Mar 05, 2026, 09:00 ET Nicoya Lifesciences Announces Launch of FastHDX™, a Millisecond HDX-MS Platform Aimed to Open New Therapeutic Opportunities
it will significantly expand how we study protein motion, disorder, and mechanism – ultimately unlocking our understanding of complex disease, biotechnology and medicines.""FastHDX is the culmination of nearly a decade of development by the Applied Photophysics team, shaped by deep external expertise
More news about: Nicoya Lifesciences Inc.
Mar 05, 2026, 09:00 ET SkylineDx Launches a Guideline-Informed Risk Assessment Initiative to Support SLNB Decision-Making in Early-Stage Melanoma
www.merlinmelanomatest.comAbout SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Mar 05, 2026, 08:30 ET Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
decoytx.com.About Decoy Therapeutics Inc. Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
ConferenceSAN FRANCISCO, March 5, 2026 /PRNewswire/ -- Therna Biosciences, a biotechnology company pioneering programmable RNA therapeutics, today announced a collaboration with Charles River to advance single-patient RNA medicines for
More news about: Therna Biosciences
Mar 05, 2026, 07:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Mar 05, 2026, 07:00 ET Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
Mass. and COPENHAGEN, Denmark, March 5, 2026 /PRNewswire/ -- Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug Administration
More news about: Hemab Therapeutics
Mar 05, 2026, 06:00 ET Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 05, 2026, 01:15 ET New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: F. Hoffman-La Roche AG
Mar 04, 2026, 20:40 ET 以千分之一劑量 CAR-T 實現血液瘤與紅斑狼瘡100%完全緩解，晶泰孵化企業萊芒生物完成近2億元融資，「平價」新型高效細胞療法開啟臨床轉化
Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術 META 10 展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology 和 Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。2022 年以來，公司累計獲得超 4 億元風險投資和項目資助，榮膺 2025 年全國 「顛覆性技術創新」 大賽最高獎項等數十項生物醫藥領域國家或省市級獎項，併入選國家重點研發計劃「顛覆性技術創新」
More news about: 晶泰科技
Mar 04, 2026, 18:01 ET Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight
This has accelerated its adoption in oncology, immunotherapy, and gene therapy.Increased R&D Investment: Pharmaceutical and biotechnology companies, along with academic institutions, are substantially investing in research to develop next-generation nanotherapeutics and nano-diagnostics.Rising
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 16:01 ET AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Mar 04, 2026, 13:00 ET Rice-led research to develop first regenerative therapy for lymphedema receives up to $18.2M federal award
RBL LLC biotechnology startup SteerBio to drive clinical development and commercializationHOUSTON, March 4, 2026 /PRNewswire/ --A team of researchers led by Rice University bioengineer Omid Veiseh
More news about: Rice University
Mar 04, 2026, 10:27 ET Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities
Level 1 certified quality systems, as well as qualification as a Class II Unsealed Radioactive Material Workplace, providing pharmaceutical and biotechnology partners with reliable, audit-ready laboratory services that meet global regulatory standards. Its strong track record includes supporting regulatory
More news about: Frontage Laboratories, Inc.
Mar 04, 2026, 09:11 ET Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
epicenter, while expanding its presence in Europe by establishing the UK Biocentre as a European-wide operational hub to support pharmaceutical, biotechnology, academic, and public health customers across the region. This major hub will support our already established biorepository in Griesheim, Germany
More news about: Azenta
Mar 04, 2026, 08:52 ET Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
creates more commercial and social values to become a global leading biopharmaceutical enterprise.About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: Akeso, Inc.
Mar 04, 2026, 08:31 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate
More news about: MetaVia Inc.
Mar 04, 2026, 08:05 ET INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 04, 2026, 07:05 ET REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Interpretation." The event will feature leading experts and take place March 9, 2026 at 12 p.m. ET.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Mar 04, 2026, 07:00 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
BOSTON, March 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the
More news about: HotSpot Therapeutics
Mar 04, 2026, 07:00 ET Matricelf Ltd. (TASE: MTLF) Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile of Its Personalized Spinal Cord Implant
prepares for advanced preclinical studies and future human clinical trials.About Matricelf Ltd.Matricelf Ltd. (TASE: MTLF) is a biotechnology company focused on developing personalized autologous regenerative therapies for spinal cord injury. The company's platform integrates stem cell
More news about: Matricelf Ltd.
Mar 03, 2026, 22:49 ET MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology.We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and
More news about: MGI TECH